Hutch News
Results per Page:
Dr. Hans-Peter Kiem speaks about HIV and making gene therapy more accessible at TEDxSeattle
His talk is now available online
Multi-step HIV-1 vaccines
From the Vaccine and Infectious Disease Division and the Chan Zuckerberg Biohub.
Science on the horizon
Fred Hutch experts make predictions for science trends, advances in 2020
CCR5 plays multiple roles in mucosal immunity
From the Prlic lab, Vaccine and Infectious Disease Division
World AIDS Day: Stepping up the search for a cure
New funding from Gates Foundation and NIH give vote of confidence for an audacious goal
HIV vaccine trial uncovers plausible mechanisms of protection
From the HVTN, Vaccine and Infectious Disease Division
Inflammatory mucosal T cells: harmful or helpful?
From the Lund lab, Vaccine and Infectious Disease Division
Tip Sheet: A clever way to make an AIDS vaccine; how a common cancer mutation actually drives cancer; and a new process that regulates red blood cell development
SEATTLE – Nov. 6, 2019 – Below are summaries of recent Fred Hutch research findings with links for additional background and media contacts.
New trial aims to curb HPV-related cancers in HIV+ women and children
International ‘dream team’ to use new technologies and prevention approaches to help those at highest risk
An old HIV vaccine surprises researchers once again
Designed for a Thailand strain of the AIDS virus, it stirred stronger immunity in South Africa
Creating antibodies with antibodies
From the McGuire, Taylor, and Stamatatos labs, Vaccine and Infectious Disease Division
Conference on gene therapy for HIV cures will highlight progress and challenges ahead
Dr. Robert Siliciano, keynote speaker, discovered why AIDS drugs alone cannot cure HIV
In Uganda: Treating twin threats of HIV and cancer
Dr. Sue Desmond-Hellmann of the Bill & Melinda Gates Foundation visits Hutch researchers in Kampala
New HIV vaccine trial to launch in U.S., Latin America and Europe
‘Mosaico’ will enroll 3,800 transgender people and men who have sex with men
Improving HIV clinical trials with mobile technology
From the HIV Vaccine Trials Network, Vaccine and Infectious Disease Division
Could gold be the key to making gene therapy for HIV and other blood disorders more accessible?
A proof-of-principle study published in Nature Materials shows that gold nanoparticles loaded with CRISPR and other gene-editing tools safely and effectively edited blood stem cells. (Photos, diagram available for media use.)
Special delivery: Gold nanoparticles ship CRISPR cargo
Fred Hutch scientists used their new golden courier to edit genes tied to HIV, genetic blood disorders
Machine learning predicts HIV pseudovirus antibody neutralization
From the Gilbert group, Vaccine and Infectious Disease Division
Could an infant’s blood sample help model a better HIV vaccine?
Tracing the evolution of a baby’s special HIV-blocking protein
Increased racial and ethnic minority participation in HIV vaccine trials
From the HIV Vaccine Trials Network, Vaccine and Infectious Disease Division